InvestorsHub Logo
Followers 971
Posts 383037
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Tuesday, 02/13/2024 12:32:09 PM

Tuesday, February 13, 2024 12:32:09 PM

Post# of 1125
"In a market environment where biotech companies have been increasingly challenged to fund clinical development, we appreciate the confidence of partners that share our view that NMDA-antagonist drugs potentially represent a new and potent class of medicines to treat bipolar depression with suicidality. Over the past six months, NRx, Lotus, and Alvogen have formed a close working relationship and we share a joint commitment to bringing this potentially life-saving drug to patients." said Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NRXP News